Hosted on MSN2mon
Anocca submits application to EMA for pancreatic cancer trial
Anocca has submitted its first clinical trial application (CTA) to the European Medicines Agency (EMA) for conducting the Phase I/II VIDAR-1 trial. The trial's commencement depends on the EMA's ...
Thiogenesis Receives Final EU Clearance of CTA to Initiate its Phase 2 Clinical Trial in MELAS
Detailed price information for Thiogenesis Therapeutics Corp (TTI-X) from The Globe and Mail including charting and trades.